Pharmacogenetics of cystic fibrosis treatment

Pharmacogenomics

Volumn 17, Issue 13, 2016, Pages 1453-1463

  Carter, Suzanne C ^a   McKone, Edward F ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

correctors; cystic fibrosis; cystic fibrosis transmembrane conductance regulator; gene therapy; genetics; ivacaftor; lumacaftor; modulators; potentiators

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME INHIBITOR; GENTAMICIN; GS 9411; IVACAFTOR; LUMACAFTOR; N 6033; N 91115; P 1037; PLACEBO; RIOCIGUAT; UNCLASSIFIED DRUG; CFTR PROTEIN, HUMAN;

CFTR GENE; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG TARGETING; FORCED EXPIRATORY VOLUME; GENE; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; GENETIC VARIATION; GENOTYPE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN PROCESSING; REVIEW; GENETICS; MUTATION;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION; PHARMACOGENETICS;

EID: 84982125532     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.16.25     Document Type: Review

References (97)

1. Ashlock MA, Olson ER. Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease. Ann. Rev. Med. 62, 107-125 (2011).
2. Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ 335(7632), 1255-1259 (2007).
3. Welsh M, Ramsey B, Accurso F, Gr C Cystic Fibrosis. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Valle D (Eds). McGraw-Hill, OH, USA, 5121-5189 (2001).
4. The Clinical and Functional TRanslation of CFTR (CFTR2). http://cftr2.org
5. Cystic Fibrosis Mutation Database (2015). www.genet.sickkids.on.ca/
6. Proesmans M, Vermeulen F, De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur. J. Pediatr 167(8), 839-849 (2008).
7. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. Am. J. Respir. Crit. Care Med.186(7), 593-597 (2012).
8. Andersen DH. Cystic Fibrosis of the pancreas and its relation to celiac disease. A clinical and pathological study. Am. J. Dis. Child 56(2), 344-399 (1938).
9. Andersen DH, Hodges RG. Celiac Syndrome V Genetics of cystic fibrosis of the pancreas with a consideration of etiology. Am. J. Dis. Child 72(1), 62-80 (1946).
10. Littlewood JM. History of cystic fibrosis. In: Cystic Fibrosis, Hodson M, Geddes D, Bush A (Eds). Hodder Arnold, London, UK, 3-19 (2007).
11. Di Sant'agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics 12(5), 549-563 (1953).
12. Davis PB. Cystic fibrosis since 1938. Am. J. Respir. Crit. Care Med. 173(5), 475-482 (2006).
13. Rommens JM, Iannuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245(4922), 1059-1065 (1989).
14. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922), 1066-1073 (1989).
15. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922), 1073-1080 (1989).
16. Scanlin TF. Cystic Fibrosis. In: Pulmonary Diseases and Disorders. Fishman AP (Ed.). McGraw-Hill 1273-1294 (1988).
17. Tsui LC, Buchwald M, Barker D et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230(4729), 1054-1057 (1985).
18. Farrall M, Law HY, Rodeck CH et al. First-trimester prenatal diagnosis of cystic fibrosis with linked DNA probes. Lancet 1(8495), 1402-1405 (1986).
19. Mcintosh I, Cutting GR. Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J. 6(10), 2775-2782 (1992).
20. Jentsch TJ, Stein V, Weinreich F, Zdebik AA. Molecular structure and physiological function of chloride channels. Physiol. Rev. 82(2), 503-568 (2002).
21. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutationspecific treatment. Chest 139(6), 1480-1490 (2011).
22. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13(24), 6076-6086 (1994).
23. Cutting GR. Cystic Fibrosis. In: Principles and Practice of Medical Genetics, Rimoin DL, Connor MJ, Pyeritz RE (Eds). Churchill Livingstone, NY, USA, 2685-2717 (1997).
24. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N. Eng. J. Med. 372(4), 351-362 (2015).
25. Pezzulo AA, Tang XX, Hoegger MJ et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487(7405), 109-113 (2012).
26. Berkebile AR, Mccray PB Jr. Effects of airway surface liquid pH on host defense in cystic fibrosis. Int. J. Biochem. Cell Biol. 52, 124-129 (2014).
27. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Ann. Rev. Med. 58, 157-170 (2007).
28. Castellani C, Cuppens H, Macek M Jr et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J. Cyst. Fibros. 7(3), 179-196 (2008).
29. Sosnay PR, Cutting GR. Interpretation of genetic variants. Thorax 69(3), 295-297 (2014).
30. Bombieri C, Claustres M, De Boeck K et al. Recommendations for the classification of diseases as CFTR-related disorders. J. Cyst. Fibros. 10(Suppl. 2), S86-S102 (2011).
31. Ooi CY, Castellani C, Keenan K et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 135(6), e1377-e1385 (2015).
32. Farrell PM, Rosenstein BJ, White TB et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J. Pediatr. 153(2), S4-s14 (2008).
33. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J. Cyst. Fibros. 13(4), 403-409 (2014).
34. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 130(5), 1441-1447 (2006).
35. Tsui LC. The spectrum of cystic fibrosis mutations. Trends Genet. 8(11), 392-398 (1992).
36. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73(7), 1251-1254 (1993).
37. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 16(1), 45-56 (2015).
38. Lim M, Zeitlin PL. Therapeutic strategies to correct malfunction of CFTR. Paediatr. Respir. Rev. 2(2), 159-164 (2001).
39. McKone EF, Velentgas P, Swenson AJ, Goss CH. Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype. J. Cyst. Fibros. 14(5), 580-586 (2015).
40. Nissim-Rafinia M, Kerem B, Kerem E. Molecular biology of cystic fibrosis: CFTR processing and functions, and classes of mutations. In: Cystic Fibrosis, Hodson M, Geddes D, Bush A (Eds). Hodder Arnold, London, UK, 49-58 (2007).
41. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J. Biol. Chem. 274(31), 21873-21877 (1999).
42. Vanscoy LL, Blackman SM, Collaco JM et al. Heritability of lung disease severity in cystic fibrosis. Am. J. Respir. Crit. Care Med.175(10), 1036-1043 (2007).
43. Drumm ML, Ziady AG, Davis PB. Genetic variation and clinical heterogeneity in cystic fibrosis. Ann Rev. Pathol. 7, 267-282 (2012).
44. Sanders DB, Li Z, Laxova A et al. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann. Am. Thorac. Soc. 11(1), 63-72 (2014).
45. Collaco JM, Blackman SM, Mcgready J, Naughton KM, Cutting GR. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J. Pediatr. 157(5), 802-807.e801-803 (2010).
46. Corvol H, Blackman SM, Boelle PY et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat. Commun. 6, 8382 (2015).
47. Smyth AR, Bell SC, Bojcin S et al. European cystic fibrosis society standards of care: best practice guidelines. J. Cyst. Fibros. 13(Suppl. 1), S23-S42 (2014).
48. Hoffman LR, Ramsey BW. Cystic fibrosis therapeutics: the road ahead. Chest 143(1), 207-213 (2013).
49. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum. Mutat. 19(6), 575-606 (2002).
50. Wilschanski M, Yahav Y, Yaacov Y et al. Gentamicininduced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Eng. J. Med. 349(15), 1433-1441 (2003).
51. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet 372(9640), 719-727 (2008).
52. Kerem E, Konstan MW, De Boeck K et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 2(7), 539-547 (2014).
53. ClinicalTrials.gov. A Phase 3 efficacy and safety study of ataluren (PTC124) in patients with nonsense mutation cystic fibrosis. (2016). https://clinicaltrials.gov/ct2/show/NCT01239306
54. Xue X, Mutyam V, Tang L et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am. J. Respir. Cell Mol. Biol. 50(4), 805-816 (2014).
55. Blanchet S, Cornu D, Argentini M, Namy O. New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae. Nucleic Acids Res. 42(15), 10061-10072 (2014).
56. Flume PA, Liou TG, Borowitz DS et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142(3), 718-724 (2012).
57. Van Goor F, Hadida S, Grootenhuis PD et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106(44), 18825-18830 (2009).
58. Pettit RS, Fellner C. CFTR modulators for the treatment of cystic fibrosis. P & T 39(7), 500-511 (2014).
59. Clancy JP, Rowe SM, Accurso FJ et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67(1), 12-18 (2012).
60. Van Goor F, Hadida S, Grootenhuis PD et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA 108(46), 18843-18848 (2011).
61. Boyle MP, Bell SC, Konstan MW et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a Phase 2 randomised controlled trial. Lancet 2(7), 527-538 (2014).
62. Wainwright CE, Elborn JS, Ramsey BW et al. Lumacaftorivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373(3), 220-231 (2015).
63. USA FDA. FDA news release: FDA approves new treatment for cystic fibrosis (2016). www.fda.gov
64. ClinicalTrials.gov. A study to evaluate the efficacy and safety of VX-661 in combination With ivacaftor in subjects aged 12 years and older with cystic fibrosis, heterozygous for the F508del-CFTR mutation (2016). https://clinicaltrials.gov/ct2/show/NCT02516410
65. ClinicalTrials.gov. Phase 3 Study of VX-661 in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, who have one F508del-CFTR mutation and a second mutation that has been demonstrated to be clinically responsive to ivacaftor. (2016). https://clinicaltrials.gov/ct2/show/NCT02412111
66. Accurso FJ, Rowe SM, Clancy JP et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Eng. J. Med. 363(21), 1991-2003 (2010).
67. Ramsey BW, Davies J, Mcelvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Eng. J. Med. 365(18), 1663-1672 (2011).
68. Davies JC, Wainwright CE, Canny GJ et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am. J. Respir. Crit. Care Med.187(11), 1219-1225 (2013).
69. McKone EF, Borowitz D, Drevinek P et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a Phase 3, open-label extension study (PERSIST). Lancet 2(11), 902-910 (2014).
70. Barry PJ, Plant BJ, Nair A et al. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest 146(1), 152-158 (2014).
71. De Boeck K, Munck A, Walker S et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J. Cyst. Fibros. 13(6), 674-680 (2014).
72. Goodman N, Watson K, Charlwood J et al. QBW251 is a novel CFTR potentiator that has been studies in healthy volunteers. Pediatr. Pulmonology 49(S38), S232-S233 (2014).
73. ClinicalTrials.gov. Safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients (2016). https://clinicaltrials.gov/ct2/show/NCT02190604
74. Moss RB, Flume PA, Elborn JS et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet 3(7), 524-533 (2015).
75. Drumm ML, Pope HA, Cliff WH et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 62(6), 1227-1233 (1990).
76. Conese M, Ascenzioni F, Boyd AC et al. Gene and cell therapy for cystic fibrosis: from bench to bedside. J. Cyst. Fibros. 10(Suppl. 2), S114-S128 (2011).
77. Gill DR, Hyde SC. Delivery of genes into the CF airway. Thorax 69(10), 962-964 (2014).
78. Prickett M, Jain M. Gene therapy in cystic fibrosis. Transl. Res. 161(4), 255-264 (2013).
79. Schuster BS, Kim AJ, Kays JC et al. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol. Ther. 22(8), 1484-1493 (2014).
80. Armstrong DK, Cunningham S, Davies JC, Alton EW. Gene therapy in cystic fibrosis. Arch Dis. Child. 99(5), 465-468 (2014).
81. Davies LA, Nunez-Alonso GA, Mclachlan G, Hyde SC, Gill DR. Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. Hum. Gene Ther. 25(2), 97-107 (2014).
82. Lee T, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosisrelated lung disease. Cochrane Database Syst. Rev. 18(2), CD005599 (2007).
83. Alton EW, Armstrong DK, Ashby D et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebocontrolled, Phase 2b trial. Lancet. 3(9), 684-691 (2015).
84. Cystic Fibrosis Foundation. https://tools.cff.org/research/drugdevelopmentpipeline/
85. Foundation CF. Drug development pipeline (2016). https://tools.cff.org/research/drugdevelopmentpipeline/
86. Chen L, Patel RP, Teng X, Bosworth CA, Lancaster JR Jr, Matalon S. Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione. J. Biol. Chem. 281(14), 9190-9199 (2006).
87. Ghofrani HA, Galie N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Eng. J. Med. 369(4), 330-340 (2013).
88. ClinicalTrials.gov. Early signs of efficacy study with riociguat in adult homozygous delta F508 cystic fibrosis patients. (2016). https://clinicaltrials.gov/ct2/show/NCT02170025
89. Zaman K, Sawczak V, Zaidi A et al. Augmentation of CFTR maturation by S-nitrosoglutathione reductase. Am. J. Physiol. Lung Cell. Mol. Physiol. 310(3), L263-L270 (2016).
90. ClinicalTrials.gov. Study of N91115 in patients with cystic fibrosis homozygous F508del-CFTR mutation (SNO4). (2016). https://clinicaltrials.gov/ct2/show/NCT02275936
91. ClinicalTrials.gov. Safety and pharmacokinetic study of N6022 in subject with cystic fibrosis homozygous for F508del-CFTR mutation (SNO-1) (2016). https://clinicaltrials.gov/ct2/show/NCT01746784
92. ClinicalTrials.gov. Study of N91115 in patients with CF homozygous for the F508del-CFTR mutation (SNO-6) (2016). https://clinicaltrials.gov/ct2/show/NCT02589236
93. Beumer W, Swildens J, Henig N et al. WS01.2 QR-010, an RNA therapy, restores CFTR function using in vitro and in vivo models of ΔF508 CFTR. J. Cyst. Fibros. 14(June), S1 (2015).
94. ClinicalTrials.gov. Dose escalation study of QR-010 in homozygous ΔF508 cystic fibrosis patients (2016). https://clinicaltrials.gov/ct2/show/NCT02532764
95. Chen JH, Stoltz DA, Karp PH et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143(6), 911-923 (2010).
96. ClinicalTrials.gov. Clearing lungs with ENAC inhibition in cystic fibrosis (2016). https://clinicaltrials.gov/ct2/show/NCT02532764
97. ClinicalTrials.gov. A randomized, double-blind, placebocontrolled multiple dose trial of GS-9411 in healthy volunteers (2016). https://clinicaltrials.gov/ct2/show/NCT00999531